91 related articles for article (PubMed ID: 10579149)
1. Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone.
Frye RF; Tammara B; Cowart TD; Bramer SL
J Clin Pharmacol; 1999 Nov; 39(11):1177-83. PubMed ID: 10579149
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
[TBL] [Abstract][Full Text] [Related]
3. Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans.
Emery MG; Jubert C; Thummel KE; Kharasch ED
J Pharmacol Exp Ther; 1999 Oct; 291(1):213-9. PubMed ID: 10490907
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress.
Leclercq I; Desager JP; Horsmans Y
Clin Pharmacol Ther; 1998 Aug; 64(2):144-9. PubMed ID: 9728894
[TBL] [Abstract][Full Text] [Related]
5. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers.
Eap CB; Schnyder C; Besson J; Savary L; Buclin T
Clin Pharmacol Ther; 1998 Jul; 64(1):52-7. PubMed ID: 9695719
[TBL] [Abstract][Full Text] [Related]
7. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity.
Dreisbach AW; Ferencz N; Hopkins NE; Fuentes MG; Rege AB; George WJ; Lertora JJ
Clin Pharmacol Ther; 1995 Nov; 58(5):498-505. PubMed ID: 7586943
[TBL] [Abstract][Full Text] [Related]
8. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
Nolin TD; Gastonguay MR; Bies RR; Matzke GR; Frye RF
Clin Pharmacol Ther; 2003 Dec; 74(6):555-68. PubMed ID: 14663458
[TBL] [Abstract][Full Text] [Related]
9. Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe.
Park JY; Kim KA; Park PW; Ha JM
J Clin Pharmacol; 2006 Jan; 46(1):109-14. PubMed ID: 16397290
[TBL] [Abstract][Full Text] [Related]
10. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats.
Rockich K; Blouin R
Drug Metab Dispos; 1999 Sep; 27(9):1074-7. PubMed ID: 10460809
[TBL] [Abstract][Full Text] [Related]
11. Circadian rhythm of cytochrome P4502E1 and its effect on disposition kinetics of chlorzoxazone in rats.
Khemawoot P; Nishino K; Ishizaki J; Yokogawa K; Miyamoto K
Eur J Pharmacol; 2007 Nov; 574(1):71-6. PubMed ID: 17651723
[TBL] [Abstract][Full Text] [Related]
12. Effect of piperine on CYP2E1 enzyme activity of chlorzoxazone in healthy volunteers.
Bedada SK; Boga PK
Xenobiotica; 2017 Dec; 47(12):1035-1041. PubMed ID: 27670974
[TBL] [Abstract][Full Text] [Related]
13. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans.
Poloyac SM; Tosheva RT; Gardner BM; Shedlofsky SI; Blouin RA
Clin Pharmacol Ther; 1999 Dec; 66(6):554-62. PubMed ID: 10613610
[TBL] [Abstract][Full Text] [Related]
14. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1.
Kharasch ED; Thummel KE; Mhyre J; Lillibridge JH
Clin Pharmacol Ther; 1993 Jun; 53(6):643-50. PubMed ID: 8513656
[TBL] [Abstract][Full Text] [Related]
15. Single-dose disulfiram does not inhibit CYP2A6 activity.
Kharasch ED; Hankins DC; Baxter PJ; Thummel KE
Clin Pharmacol Ther; 1998 Jul; 64(1):39-45. PubMed ID: 9695717
[TBL] [Abstract][Full Text] [Related]
16. In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans.
Doroshyenko O; Fuhr U; Kunz D; Frank D; Kinzig M; Jetter A; Reith Y; Lazar A; Taubert D; Kirchheiner J; Baum M; Eisenbrand G; Berger FI; Bertow D; Berkessel A; Sörgel F; Schömig E; Tomalik-Scharte D
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):433-43. PubMed ID: 19190172
[TBL] [Abstract][Full Text] [Related]
17. Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats.
Khemawoot P; Yokogawa K; Shimada T; Miyamoto K
Biochem Pharmacol; 2007 Jan; 73(1):155-62. PubMed ID: 17049493
[TBL] [Abstract][Full Text] [Related]
18. Effect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone.
Koneru B; Cowart DT; Noorisa M; Kisicki J; Bramer SL
J Clin Pharmacol; 1998 May; 38(5):429-32. PubMed ID: 9602955
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol Pretreatment Affects CYP2E1 Activity of Chlorzoxazone in Healthy Human Volunteers.
Bedada SK; Neerati P
Phytother Res; 2016 Mar; 30(3):463-8. PubMed ID: 26680654
[TBL] [Abstract][Full Text] [Related]
20. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms.
Kim RB; O'Shea D
Clin Pharmacol Ther; 1995 Jun; 57(6):645-55. PubMed ID: 7781264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
